Methicillin-resistant
Staphylococcus aureus (MRSA) infections account for an estimated 23,000 deaths
per year in the United States alone. While current diagnostic testing
procedures can take up to three days, Zenosense, Inc. (OTCQB: ZENO), in concert
with development partner Zenon Biosystem, is developing a new, low cost sensor
platform that will help decrease diagnosis times and, potentially, save the
lives of millions of patients around the world.
The company’s technology
will depend on the presence of Volatile Organic Compounds (VOCs), which are
emitted by MRSA infections long before other symptoms become visible, making
earlier intervention a distinct possibility. The diagnostic tool is currently
being developed in two unique forms, including a wearable device designed to be
positioned directly on patients and medical staff, as well as a fixed device
engineered to consistently monitor a specified area in which the potential for
infection is present, such as a hospital room.
According to reports from
the Center for Disease Control, while MSRA infections in the community are
typically relatively minor, those in medical facilities commonly cause
life-threatening bloodstream infections, pneumonia and surgical site
infections. The contaminations are particularly dangerous because the presence
of two subpopulations, of which only one may be resistant to antibiotic
treatment, can seriously hamper the accuracy of existing detection methods.
Through its unique VOC sensor, Zenosense is preparing to address the serious
flaws present in current MSRA detection options.
Zenosense began its
development program of an MRSA infection sensing device in December 2013. Phase
I activity on the project includes substantial engineering work, as the company
expects greater than 90% sensitivity for the detection of MRSA-specific VOCs in
patients.
As antibiotic-resistant
bacteria threatens to return us to the time when simple infections were often
fatal, the early and accurate detection of these contagions is the only way to
minimize health risks. With Zenosense continuing its development of a
revolutionary VOC sensing MRSA diagnostic device, the company could be in
position for massive demand from the global healthcare industry in the near
future.
For more information on
the company, visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment